- Home
- NAAS vs BTAI Comparison
NAAS vs BTAI Comparison
Compare NAAS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAAS | BTAI |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4M | 35.6M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | NAAS | BTAI |
|---|---|---|
| Price | $2.99 | $1.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 7.8K | ★ 735.8K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $197.82 |
| Revenue Next Year | N/A | $910.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.49 | $1.01 |
| 52 Week High | $4.54 | $8.08 |
Technical Indicators
Market Signals| Indicator | NAAS | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 66.18 | 50.64 |
| Support Level | $2.23 | $1.02 |
| Resistance Level | $3.43 | $1.26 |
| Average True Range (ATR) | 0.22 | 0.08 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 86.84 | 55.71 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.